See All AI Secures $33M to Launch Groundbreaking AI-Based 3D Surgical Imaging and Navigation Platform

Nashua, NH — See All AI, a cutting-edge medical technology company, has raised $33 million in funding to accelerate development and future commercialization of its revolutionary AI-based platform for intraoperative 3D imaging and navigation. The system transforms traditional 2D fluoroscopic X-rays into high-resolution, navigable 3D volumes, eliminating the need for CTs, MRIs, or additional imaging hardware during surgery.

Transforming Surgery with AI

Leveraging artificial intelligence, deep learning, and machine vision, See All AI’s platform produces 1mm cross-sectional slices from just two standard fluoroscopic scans. These 3D models allow for real-time visualization and surgical planning comparable to CT-quality imaging — but with lower radiation, reduced cost, and without disrupting existing surgical workflows.

The system is especially suited for minimally invasive surgeries (MIS), requiring no direct line-of-sight between the camera and the patient’s anatomy. It is fully compatible with standard surgical drapes and positioning setups, integrating smoothly into any operating room environment.

A Software-First, Open Ecosystem

“Our platform takes a revolutionary, software-first approach,” said Eric Major, CEO of See All AI. “It works with existing fluoroscopy units to deliver advanced 3D imaging and navigation at a fraction of the cost and complexity of traditional systems. No capital expense, no closed ecosystems — just accessible, high-precision imaging for all.”

The technology pairs with the company’s proprietary “Track All” visible-light camera, offering sub-millimeter tracking of surgical instruments. Unlike other systems, it does not require markers, emitters, or line-of-sight, improving flexibility and ease of use.

With over 150,000 fluoroscopy units in use globally, the platform is designed to integrate directly with existing infrastructure or connect to See All AI’s cloud-based digital ecosystem.

Reducing Radiation and Complexity

Studies show that a single spinal CT scan delivers over 3,100% more radiation than a standard fluoroscopy image. By replacing intraoperative CT with its AI-driven 3D imaging, See All AI aims to dramatically reduce radiation exposure, shorten procedures, and lower operating costs.

“This isn’t just innovation for the sake of it,” said Dr. Todd Albert, Chief Medical Officer at See All AI and Surgeon-in-Chief Emeritus at Hospital for Special Surgery in New York. “We’re solving real problems — cutting complexity, radiation, OR time, and cost, all without changing surgeons’ tools or workflows.”

Positioned for Global Impact

Gene Gregerson, Founder and Chief Innovation Officer of See All AI, brings deep expertise, having previously pioneered the O-arm and Airo systems for intraoperative 3D imaging. “With this funding secured and core patents advancing, See All AI is positioned to lead a new category in surgical imaging,” he said.

Regulatory Pathway

While the platform has demonstrated success in preclinical testing using cadaveric subjects, it is not yet FDA-cleared or available for clinical use. The company plans to submit for FDA approval in 2025.

About See All AI:
Headquartered in Nashua, New Hampshire, See All AI is developing AI-powered surgical imaging solutions that eliminate the need for bulky, high-radiation hardware. By using existing X-ray equipment and advanced AI, the company aims to make world-class surgical imaging scalable, affordable, and globally accessible